The management of allergic eye diseases in primary eye care

Contact Lens and Anterior Eye

Volumn 32, Issue 6, 2009, Pages 260-272

  Chigbu, DeGaulle I ^a  

^a SALUS UNIVERSITY   (United States)

Author keywords

Allergic eye diseases; Non pharmacologic management; Pharmacologic management

Indexed keywords

ALLERGEN; ANTAZOLINE; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; AZELASTINE; CETIRIZINE; CHEMOKINE; CHLORPHENIRAMINE; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; CYTOKINE; EMEDASTINE; EPINASTINE; HISTAMINE RECEPTOR; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; KETOTIFEN; LEVOCABASTINE; LODOXAMIDE TROMETAMOL; LUBRICATING AGENT; NAPHAZOLINE; NEDOCROMIL SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; PEMIROLAST; PHENIRAMINE; PHENYLEPHRINE; T LYMPHOCYTE ANTIBODY; UNINDEXED DRUG; VASOCONSTRICTOR AGENT;

ALLERGIC CONJUNCTIVITIS; ANTICHOLINERGIC EFFECT; ATOPIC KERATOCONJUNCTIVITIS; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL FEATURE; CONJUNCTIVITIS; DIFFERENTIAL DIAGNOSIS; DRUG RECEPTOR BINDING; ECZEMATOID BLEPHAROCONJUNCTIVITIS; EOSINOPHIL; EYE ALLERGY; EYE CARE; FOLLICULAR CONJUNCTIVITIS; FOREIGN BODY REACTION; GIANT PAPILLARY CONJUNCTIVITIS; HUMAN; HYPEREMIA; IMMUNOPATHOGENESIS; INJECTION SITE BURNING; INJECTION SITE STINGING; MAINTENANCE THERAPY; MAST CELL; MOLECULAR MECHANICS; MYDRIASIS; PALLIATIVE THERAPY; PATIENT CARE PLANNING; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PRURITUS; QUALITY OF LIFE; REVIEW; VERNAL CONJUNCTIVITIS;

ADRENAL CORTEX HORMONES; CONJUNCTIVITIS, ALLERGIC; HUMANS; IMMUNOLOGIC FACTORS; PRIMARY HEALTH CARE;

EID: 70449558763     PISSN: 13670484     EISSN: 14765411     Source Type: Journal    
DOI: 10.1016/j.clae.2009.08.002     Document Type: Review

References (98)

1. Leonardi A. Emerging drugs for ocular allergy. Expert Opin Emerg Drugs 10 3 (2005) 505-520
2. Abelson M.B., Leonardi A., and Smith L. The mechanisms, diagnosis and treatment of allergy. Rev Ophthalmol 9 4 (2002) 74-84
3. Pavesio C.E., and Decory H.H. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol 92 4 (2008) 455-459
4. Pawankar R. Inflammatory mechanisms in allergic rhinitis. Curr Opin Allergy Clin Immunol 7 (2007) 1-4
5. Reiss J., Abelson M.B., George M.A., and Wedner H.J. Allergic conjunctivitis. In: Pepose J.S., Holland G.N., and Wilhelmus K.R. (Eds). Ocular infection and immunity (1996), Mosby, St. Louis 345-358
6. Berdy G.J. Atopic keratoconjunctivitis. Acta Ophthalmol Scand 77 Suppl. 228 (1999) 7-9
7. Stahl J.L., Cook E.B., Barney N.P., and Grziano F.M. Pathophysiology of ocular allergy: the roles of conjunctival mast cells and epithelial cells. Curr Allergy Asthma Rep 2 4 (2002) 332-339
8. Leonardi A. Pathophysiology of allergic conjunctivitis. Acta Ophthalmol Scand 77 Suppl. 228 (1999) 21-23
9. McGill J.I., and Bacon A. Allergic eye disease mechanisms. Br J Ophthalmol 82 (1998) 1203-1214
10. Okayama Y., Hagaman D.D., and Metcalfe D.D. A comparison of mediators released or generated by IFN-gamma-treated human mast cells following aggregation of Fc gamma RI or Fc epsilon RI. J Immunol 166 April (7) (2001) 4705-4712
11. Woolhiser M.R., Okayama Y., Gilfillan A.M., and Metcalfe D.D. IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma. Eur J Immunol 31 11 (2001) 3298-3307
12. Tkaczyk C., Okayama Y., Metcalfe D.D., and Gilfillan A.M. Fcgamma receptors on mast cells: activatory and inhibitory regulation of mediator release. Int Arch Allergy Immunol 133 3 (2004) 305-315
13. Tkaczyk C., Okayama Y., Woolhiser M.R., Hagaman D.D., Gilfillan A.M., and Metcalfe D.D. Activation of human mast cells through the high affinity IgG receptor. Mol Immunol 38 16-18 (2002) 1289-1293
14. Chigbu D.I. The pathophysiology of ocular allergy: a review. Contact Lens Anterior Eye 32 1 (2009) 3-15
15. Kirkner R. Lose the CAT ... and other pearls from allergists. Rev Optom 138 3 (2001) 94-98
16. Bielory L. Ocular allergy guidelines: a practical treatment alogrithm. Drugs 62 11 (2002) 1611-1634
17. Abelson M.B., and Grant A. What to do when you see red. Rev Ophthalmol 8 12 (2001) 44-47
18. Bielory L. Ocular allergy treatment. Immunol Allergy Clin North Am 28 1 (2008) 1-23
19. Bielory L. Ocular allergy treatment. Immunol Allergy Clin North Am 28 1 (2008) 189-224
20. Shovlin J.P., and DePaolis M.D. Drops to prevent dropouts. Rev Optom 137 Part 4 (2000) 69-75
21. Bielory L., Katelaris C.H., Lightman S., and Naclerio R.M. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed 9 3 (2007) 35
22. Butrus S., and Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 18 4 (2005) 485-492
23. Berdy G.J., Stoppel J.O., and Epstein A.B. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther 24 6 (2002) 918-929
24. Abelson M.B., and Gomes P.J. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin Drug Metab Toxicol 4 4 (2008) 453-461
25. D'Arienzo P.A., Leonardi A., and Bensch G. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen model. Clin Ther 24 3 (2002) 409-416
26. Discepola M., Deschenes J., and Abelson M.B. Comparison of the topical ocular anti-allergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol Scand 77 Suppl. 228 (1999) 43-46
27. Noble S., and McTavish D. Levocabastine an update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Drugs 50 6 (1995) 1032-1049
28. Deschenes J., Discepola M., and Abelson M.B. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand 77 Suppl. 228 (1999) 47-52
29. Butrus S., Greiner J.V., Discepola M., and Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 22 12 (2000) 1462-1472
30. Katelaris C.H., Ciprandi G., Missotten L., Turner F.D., Bertin D., and Berdeaux G. A Comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 24 10 (2002) 1561-1575
31. Abelson M.B., and Schwartz E. How to battle seasonal allergy. Rev Ophthalmol 5 3 (1999) 118-122
32. Ciprandi G., Buscaglia S., Catrullo A., Pesce G., Fiorino N., Montagna P., et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 27 (1997) 182-191
33. Spangler D.L., Bensch G., and Berdy G.J. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 23 8 (2002) 1272-1280
34. Bielory L. Ocular allergy treatments. Clin Rev Allergy Immunol 20 2 (2001) 201-213
35. Giede C., Metzenauer P., Petzold U., and Ellers-Lenz B. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr Med Res Opin 16 3 (2000) 153-163
36. Lawrenson J.G. Recent changes in the use and supply of medicines by optometrists. Optom Today 45 11 (2005) 28-32
37. Greiner J.V., Michaelson C., McWhirter C.L., and Shams N.B.K. Single dose of ketotifen fumarate 0.025% versus 2 weeks of cromolyn sodium 4% for allergic conjunctivitis. Adv Ther 19 4 (2002) 185-193
38. Trattler W.B., Luchs J., and Majmudar P. Elestat (epinastine HCl ophthalmic solution 0.05%) as a therapeutic for allergic conjunctivitis. Int Ophthalmol Clin 46 4 (2006) 87-99
39. Friedlaender M.H. Epinastine in the management of ocular allergic disease. Int Ophthalmol Clin 46 4 (2006) 85-86
40. Abelson M.B., Smith L., and Chapin M. Ocular allergic disease: mechanism, disease sub-types, treatment. Ocular Surf 1 3 (2003) 127-146
41. Leonardi A. The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep 2 4 (2002) 325-331
42. Bonini S., Lambiase A., Sgrulletta R., and Bonini S. Allergic chronic inflammation of the ocular surface in vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol 3 5 (2003) 381-387
43. Tauber J. Nedocromil sodium ophthalmic solution 2% twice daily in patients with allergic conjunctivitis. Adv Ther 19 2 (2002) 73-84
44. Verin P.H., Dicker I.D., and Mortemousque B. Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis. Clin Exp Allergy 29 4 (1999) 529-539
45. Alexander M., Allegro S., and Hicks A. Efficacy and acceptability of nedocromil sodium 2% and olopatadine hydrochloride 0.1% in perennial allergic conjunctivitis. Adv Ther 17 3 (2000) 140-147
46. Verin P. Treating severe eye allergy. Clin Exp Allergy 28 Suppl. 6 (1998) 44-48
47. Ashrafzadeh A., and Raizman M.B. New modalities in the treatment of ocular allergy. Int Ophthalmol Clin J 43 1 (2003) 105-110
48. Ilyas H., Slonim C.B., Braswell G.R., Favetta J.R., and Schulman M. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 30 1 (2004) 10-13
49. Durham S.R. The inflammatory nature of allergic disease. Clin Exp Allergy 28 Suppl. 6 (1998) 20-24
50. Melton R., and Thomas R. Clinical guide to ophthalmic drugs. Rev Optom 140 Suppl. 6 (2003) 33A-39A
51. Abelson M.B., and Chapin M.J. The ophthalmic drug pipeline. Rev Ophthalmol 7 5 (2000) 120-124
52. Abelson M.B., Hallas S., Colby K., and Protopic:. A new ally against inflammation. Rev Ophthalmol 9 4 (2002) 104-107
53. Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan. Clin Drug Investig 26 5 (2006) 235-246
54. Cheer S.M., and Plosker G.L. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2 6 (2001) 389-406
55. Katsarou A., Armenaka M., Vosynioti V., Lagogianni E., Kalogeromitros D., and Katsambas A. Tacrolimus ointment 0.1% in the treatment of allergic contact eyelid dermatitis. J Eur Acad Dermatol Venereol 23 4 (2009) 382-387
56. Paller A.S., Eichenfield L.F., Kirsner R.S., Shull T., Jaracz E., Simpson E.L., et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics 122 6 (2008) e1210-e1218
57. Miyazaki D., Tominaga T., Kakimaru-Hasegawa A., Nagata Y., Hasegawa J., and Inoue Y. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 115 6 (2008) 988-992
58. Anand MK. Immediate hypersensitivity reactions; 2004. [Retrieved on March 10, 2006 from http://www.emedicine.com/med/topic1101.htm].
59. Brody J.M., and Foster C.S. Vernal conjunctivitis. In: Pepose J.S., Holland G.N., and Wilhelmus K.R. (Eds). Ocular infection and immunity (1996), Mosby, St. Louis 367-375
60. Dinowitz M., Rescigno R., and Bielory L. Ocular allergic disease: differential diagnosis, examination techniques, and testing. Clin Allergy Immunol 15 (2000) 127-150
61. Park A.Y., and Scott P. IL-12: keeping cell-mediated immunity alive. Scand J Immunol 53 (2001) 529-532
62. Crampton H.J. A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by conjunctival allergen challenge model. Clin Ther 24 11 (2002) 1800-1808
63. Lemanske Jr. R.F., and Kakliner M.A. Late phase allergic reactions. Int J Dermatol 22 7 (1983) 401-409
64. Abelson M.B., and Rosner S.A. How to handle drug-induced allergic conjunctivitis. Rev Ophthalmol 6 10 (1999) 146-148
65. Donshik P.C. Contact lens chemistry and giant papillary conjunctivitis. Eye Contact Lens 29 Suppl. 1 (2003) S37-S39 [discussion S57-9, S192-4]
66. Sindt C.W., and Longmuir R.A. Contact lens strategies for the patient with dry eye. Ocul Surf 5 4 (2007) 294-307
67. Stahl J.L., and Barney N.P. Ocular allergic disease. Curr Opin Allergy Clin Immunol 4 (2004) 455-459
68. Ono S.J., and Abelson M.B. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 115 1 (2005) 118-122
69. Siddique M., Manzouri B., Flynn T.H., and Ono S.J. Allergy and contact lenses. Chem Immunol Allergy 92 (2007) 166-175
70. Tan M.E., Demirci G., Pearce D., Jalbert I., Sankaridurg P., and Willcox M.D. Contact lens-induced papillary conjunctivitis is associated with increased albumin deposits on extended wear hydrogel lenses. Adv Exp Med Biol 506 Pt B (2002) 951-955
71. Michaud L., and Giasson C.J. Overwear of contact lenses: increased severity of clinical signs as a function of protein adsorption. Optom Vis Sci 79 3 (2002) 184-192
72. Maldonado-Codina C., and Efron N. Impact of manufacturing technology and material composition on the clinical performance of hydrogel lenses. Optom Vis Sci 81 6 (2004) 442-454
73. Katelaris C.H. Giant papillary conjunctivitis-a review. Acta Ophthalmol Scand 77 Suppl. 228 (1999) 17-20
74. Donshik P.C., Ehler W.H., and Ballow M. Giant papillary conjunctivitis. Immunol Allergy Clin North Am 28 1 (2008) 83-103
75. Abelson M.B., George M.A., and Garofalo C. Differential diagnosis of ocular allergic disorders. Ann Allergy 70 Part 2 (1993) 95-109
76. Chigbu D.I. Allergic eye disease a review of the clinical features, differential diagnosis and diagnoses. Optom Today 46 15 (2006) 35-38
77. Bielory L. Differential diagnosis of conjunctivitis for clinical allergist-immunologists. Ann Allergy Asthma Immunol 98 (2007) 105-115
78. Leonardi A., and Secchi A.G. Vernal keratoconjunctivitis. Int Ophthalmol Clin J 43 1 (2003) 41-58
79. Lemp M.A. Contact lenses and allergy. Curr Opin Allergy Clin Immunol 8 5 (2008) 457-460
80. Cameron J.A. Shield ulcers and plaques of the cornea in vernal keratoconjunctivitis. Ophthalmology 102 6 (1995) 985-993
81. Buckley R.J., and Bacon A.S. Giant papillary conjunctivitis. In: Pepose J.S., Holland G.N., and Wilhelmus K.R. (Eds). Ocular infection and immunity (1996), Mosby, St. Louis 359-366
82. Zhan H., Smith L., Calder V., Buckley R., and Lightman S. Clinical and immunological features of atopic keratoconjunctivitis. Int Ophthalmol Clin J 43 1 (2003) 59-72
83. Nishida T., and Taylor A.W. Specific aqueous humour factors induce activation of regulatory T cells. Invest Ophthalmol Visual Sci 40 10 (1999) 2268-2274
84. Berdy G.J. Atopic Keratoconjunctivitis. Acta Ophthalmol Scand 77 Suppl. 228 (1999) 7-9
85. Buckley R.J. Allergic eye disease-a clinical challenge. Clin Exp Allergy 28 (1998) 39-43
86. Casey R., and Abelson M.B. Atopic keratoconjunctivitis. Int Ophthalmol Clin 37 2 (1997) 111-117
87. Schmid K.L., and Schmid L.M. Ocular allergy: causes and therapeutic options. Clin Exp Optom 83 5 (2000) 257-270
88. Kapp A., Allen B.R., and Reitamo S. Atopic dermatitis management with tacrolimus ointment (Protopic). J Dermatolog Treat 14 Suppl. 1 (2003) 5-16
89. Lemp M.A., and Bielory L. Contact lenses and associated anterior segment disorders: dry eye disease, blepharitis, and allergy. Immunol Allergy Clin North Am 28 1 (2008) 105-117
90. Elher W.H., and Donshik P.C. Giant papillary conjunctivitis. Curr Opin Allergy Clin Immunol 8 (2008) 445-449
91. Donshik P.C. Giant papillary conjunctivitis. Trans Am Ophthalmol Soc 92 (1994) 687-744
92. Porazinski A.D., and Donshik P.C. Giant papillary conjunctivitis in frequent replacement contact lens wearers: a retrospective study. CLAO J 25 3 (1999) 142-147
93. Kymionis G.D., Goldman D., Ide T., and Yoo S.H. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea 27 2 (2008) 228-229
94. Foulks G.N., Harvey T., and Raj C.V. Therapeutic contact lenses: the role of high-Dk lenses. Ophthalmol Clin North Am 16 3 (2003) 455-461
95. Chigbu D.I. Allergic eye disease a review of their management. Optom Today 46 16 (2006) 35-38
96. Bonini S., Sacchetti M., Mantelli F., and Lambiase A. Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol 7 5 (2007) 436-441
97. Calonge M., and Herreras J.M. Clinical grading of atopic keratoconjunctivitis. Curr Opin Allergy Clin Immunol 7 5 (2007) 442-445
98. Keklikci U., Soker S.I., Sakalar Y.B., Unlu K., Ozekinci S., and Tunik S. Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. Jpn J Ophthalmol 52 5 (2008) 357-362